Rome

• A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1 Pending
  2025-523911-13-00 5 Narcolepsy Type 1
• Maintenance AVElumab after SECond line platinum-based chemotherapy for metastatic urothelial carcinoma: AVESEC trial – GOIRC-02-2025 Pending
  2025-524077-16-00 4 metastatic urothelial carcinoma
• A study of cemsidomide and dexamethasone in subjects with relapsed or refractory multiple myeloma (r/r MM) Pending
  2025-524181-26-00 4 relapsed/refractory multiple myeloma
• BETRI-Prospective: Asthma control in Single Inhaler ICS/LABA/LAMA (87/5/9 pMDI [BDP/FF/GB - 100/6/12.5 µg]) vs Single Inhaler ICS/LABA (200/ … Pending
  2025-524289-56-00 6 Asthma
• A medical research to evaluate if MaaT013 is safe and helps children and adolescent with GI-aGvHD after failed two prior therapies. Pending
  2025-524302-15-00 4 Gastrointestinal Acute Graft-versus-Host Disease (GI-aGvHD)
• A Phase 3 Study of Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis Pending
  2025-524316-11-00 5 Primary Progressive Multiple Sclerosis (PPMS)
• An open-label, single-arm extension study to evaluate the long-term safety, tolerability, and efficacy of KL1333 (napazimone) in patients wi … Pending
  2025-524367-20-00 4 Adult patients with primary mitochondrial disease
• Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia Pending
  2025-524810-28-00 5 Acute Promyelocytic Leukemia
• A trial to learn how safe different combinations of anti-cancer drugs are and how well they work in adults with advanced or metastatic non-s … Pending
  2025-524843-11-00 4 Non-Small Cell Lung Cancer
• A Multicenter Randomized Controlled Trial Assessing the Efficacy and Safety of Recombinant Human Follicle Stimulating Hormone (r-hFSH-alfa o … Pending
  2025-525005-20-00 6 Male Infertility
• EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab … Pending
  2026-525248-13-00 9 Advanced Solid Tumors
• A Phase 2 Study of JNJ-79635322 in Participants with RRMM Recruiting
  2025-521976-80-00 4 2026-05-28 Relapsed or Refractory Multiple Myeloma (RRMM)
• A Phase 2 Platform Study to Evaluate Therapies for Inflammatory Bowel Disease Recruiting
  2025-522001-38-00 4 2026-05-27 Crohn’s Disease
• A Phase 3 Study Comparing JNJ-79635322 and an anti-BCMAxCD3 Bispecific Antibody in Participants with Relapsed or Refractory Multiple Myeloma Recruiting
  2025-522007-18-00 5 2026-05-27 Relapsed or Refractory Multiple Myeloma
• Long-Term Safety Study of Deucravacitinib versus Ustekinumab in Participants with Psoriasis (PRAGMATYK) Recruiting
  2023-503766-24-00 11 2026-05-26 Moderate to Severe Plaque Psoriasis
• A clinical study to evaluate the effects of RO7795068 in participants with obesity or overweight and type 2 diabetes Recruiting
  2025-523106-32-00 5 2026-05-25 Obesity or Overweight and Type 2 Diabetes
• A Long-Term Extension Study of IMVT-1402 in Adult Patients With Graves' Disease Recruiting
  2025-524001-33-00 4 2026-05-22 Graves’ Disease
• A Double-blind, Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults with Focal Seizures Recruiting
  2025-524038-24-00 5 2026-05-22 Focal Epilepsy
• A Study of KT-621 Administered Orally to Adult Participants with Moderate to Severe Eosinophilic Asthma Recruiting
  2025-523180-38-00 4 2026-05-21 Uncontrolled Moderate to Severe Eosinophilic Asthma
• AURA-IPF: A Randomized Phase 2 Study to evaluate the safety and efficacy of AP02 (nintedanib solution) in IPF Recruiting
  2025-523431-19-00 4 2026-05-20 Idiopathic Pulmonary Fibrosis (IPF)
• An Open-label Study to evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in children with gMG Recruiting
  2025-520993-20-00 4 2026-05-19 Generalized Myasthenia Gravis
• Study to assess the efficacy and safety of Rina-S in participants with non-small cell lung cancer Recruiting
  2025-522107-18-00 4 2026-05-19 Locally advanced or metastatic Non-Small Cell Lung Cancer
• Inavolisib for PIK3CA mutated advanced endometrial cancer: a multicentric, phase II, MITO END-4 trial Recruiting
  2025-522981-61-00 4 2026-05-19 endometrial cancer
• A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants with Platinum-Resistant (Part A) and Platinum-Sensitive (Part B … Recruiting
  2025-522255-25-00 5 2026-05-18 Fallopian Tube Neoplasms

Showing 169–192 of 2,096 trials